GSK 1120212

Known as: GSK-1120212, GSK1120212, MEK Inhibitor GSK1120212 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
051020092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
No effective targeted therapy is currently available for NRAS mutant melanoma. Experimental MEK inhibition is rather toxic and… (More)
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this… (More)
Is this relevant?
2013
2013
Mutations of the oncogene KRAS are important drivers of pancreatic cancer progression. Activation of epidermal growth factor… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Recent results from clinical trials with the BRAF inhibitors GSK2118436 (dabrafenib) and PLX4032 (vemurafenib) have shown… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers… (More)
Is this relevant?
2012
2012
PURPOSE Activating Q209L/P mutations in GNAQ or GNA11 (GNAQ/11) are present in approximately 80% of uveal melanomas. Mutant GNAQ… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
Highly Cited
2011
Highly Cited
2011
CRA8503 Background: In preclinical models, the BRAF/MEK inhibitor (i) combination GSK436/GSK212 has demonstrated enhanced… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The MAPK pathway is one of the most important pathways for novel anticancer drug development. We performed high-throughput… (More)
  • table I
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE Despite their preclinical promise, previous MEK inhibitors have shown little benefit for patients. This likely reflects… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
2011
2011
3085 Background: The RAS/RAF/MEK and PI3K/AKT pathways are activated in many human cancers. GSK212 is a potent and selective… (More)
Is this relevant?